ursodeoxycholic acid / Generic mfg. - LARVOL DELTA

Abnormalities of liver sinusoidal endothelial cells in primary biliary cholangitis. (PubMed, World J Exp Med) - "Endothelial adhesion molecules are abnormal in PBC particularly in the late fibrotic stages. ET and their receptors are reduced in LSECs after incubation with PBC and HCV sera, findings that might be related to pathogenesis."

Journal • Fibrosis • Hepatitis C • Hepatology • Immunology • Infectious Disease • Inflammation • Primary Biliary Cholangitis • EDN1 • EDN3 • ICAM1 • VCAM1

HA330-II HEMOADSORPTION IN THE MANAGEMENT OF ACUTE KIDNEY INJURY AND INTRAHEPATIC CHOLESTASIS OF PREGNANCY: A CASE REPORT (ISN-WCN 2026) - "Medications included doxylamine-pyridoxine, ferrous sulfate-folic acid, calcium carbonate, ursodeoxycholic acid, Hepatek, and prenatal vitamins. With clinical and laboratory improvement, the patient was transferred to the regular ward and discharged without need for long-term dialysis.Download: Download high-res image (240KB)Download: Download full-size imageDownload: Download high-res image (251KB)Download: Download full-size imageDownload: Download high-res image (243KB)Download: Download full-size imageConclusion HA 330-II hemoperfusion may benefit obstetric liver disorders by reducing inflammation and bile acids, potentially improving maternal-fetal outcomes."

Case report • Clinical • Acute Kidney Injury • Cholestasis • Hematological Disorders • Hepatology • Inflammation • Nephrology • Obstetrics • Rare Diseases • Renal Disease

MANAGEMENT OF EARLY ONSET ACUTE FATTY LIVER OF PREGNANCY WITH DOUBLE PLASMA MOLECULAR ADSORPTION SYSTEM IN A 36-YEAR-OLD FILIPINO WOMAN: A CASE REPORT (ISN-WCN 2026) - "The patient was started on supportive therapy including Minophagen infusion, ursodeoxycholic acid, vitamin K, antibiotics, methyldopa, and folate...Although AFLP is classically a late-pregnancy condition, clinicians should maintain vigilance for earlier occurrences. DPMAS may serve as a valuable adjunct in managing severe hepatic dysfunction during pregnancy, offering a bridge to recovery until liver function normalizes."

Case report • Clinical • Autoimmune Hepatitis • Cholestasis • CNS Disorders • Hepatic Encephalopathy • Hepatology • Immunology • Infectious Disease • Inflammation • Liver Failure • Metabolic Disorders • Nephrology • Obstetrics • Renal Disease

EXPERIENCE WITH AVACOPAN FOR THE TREATMENT OF ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY (ANCA)-ASSOCIATED VASCULITIS (AAV) IN THE NEPHROLOGY DEPARTMENT OF NISHI-KOBE MEDICAL CENTER. (ISN-WCN 2026) - "Concomitant immunosuppressive agents included cyclophosphamide in 6 patients, rituximab in 2, azathioprine in 5, and mizoribine in 6; 2 patients underwent plasma exchange.Clinical remission was achieved in 85% of patients at 26 weeks...Avacopan was restarted at a lower dose in all cases—one with concomitant ursodeoxycholic acid and another after alcohol abstinence. No infections requiring hospitalization were observed during the observation periodConclusion Avacopan appeared to be a safe and effective glucocorticoid-sparing therapeutic option for AAV. However, regular monitoring of liver function is warranted.I have potential conflict of interest to disclose.I have received lecture fees from KISSEI PHARMACEUTICAL CO.,LTD.I did not use generative AI and AI-assisted technologies in the writing process."

ANCA Vasculitis • Atherosclerosis • Cardiovascular • Infectious Disease • Nephrology • Rare Diseases • Vasculitis

A CASE OF VANISHING BILE DUCT SYNDROME (VBDS) CAUSED BY AVACOPAN (AVA) ADMINISTRAION FOR TREATMENT OF MICROSCOPIC POLYANGIITIS (MPA) (ISN-WCN 2026) - "A week after PSL administration, AVA and rituximab (RTX) were added...She was treated with ursodeoxycholic acid and glucocorticoid (including 1,000mg/day mPSL). For liver injury due to AVA, mycophenolate mofetil (MMF) was added...Therefore, we referred her to university hospital for consideration of liver transplantation.Conclusion We experienced a case of VBDS caused by AVA administration for treatment of MPA. When we are planning to dose the patients to AVA during remission induction therapy for MPA, we should pay attention to risks of liver injury and consider frequent laboratory follow-ups."

Clinical • ANCA Vasculitis • Glomerulonephritis • Hepatology • Liver Failure • Lupus Nephritis • Vasculitis • MPO

NALFURAFINE FOR REFRACTORY UREMIC AND CHOLESTATIC PRURITUS IN A HEMODIALYSIS PATIENT: A CASE REPORT (ISN-WCN 2026) - "During her course, she experienced recurrent spontaneous bacterial peritonitis (pathogen: vancomycin-resistant Enterococcus faecium) necessitating multiple courses of broad-spectrum antibiotics (including cefoperazone-sulbactam, meropenem, daptomycin, linezolid)...Initially suspected as a drug allergy, all potential culprit medications were discontinued, and prednisone was administered...Despite trials of various standard therapies including antihistamines, intensified hemodialysis with hemoperfusion, gabapentin, ursodeoxycholic acid, sertraline, topical tacrolimus ointment, and achieving targets for phosphate and parathyroid hormone control, the generalized pruritus remained refractory...This outcome underscores its mechanistic advantage and potential therapeutic value in challenging clinical scenarios involving mixed-origin pruritus.Conclusion In conclusion, nalfurafine presents a promising therapeutic option for refractory pruritus of mixed uremic and cholestatic..."

Case report • Clinical • Chronic Kidney Disease • Dermatology • Fibrosis • Hepatology • Immunology • Infectious Disease • Inflammation • Liver Cirrhosis • Liver Failure • Nephrology • Pruritus • Renal Disease • Urticaria

TWO CASES OF VANISHING BILE DUCT SYNDROME FOLLOWING INITIATION OF AVACOPAN THERAPY FOR ANCA-ASSOCIATED VASCULITIS. (ISN-WCN 2026) - "After remission induction therapy with glucocorticoids, rituximab, and plasma exchange, avacopan (60 mg daily) was initiatedto facilitate rapid tapering of steroids...Despite discontinuation of avacopan and initiation of ursodeoxycholic acid (UDCA), liver dysfunction persisted, his general condition consequently worsened, and he ultimately died...VBDS associated with avacopan is a very rare but potentially severe form of DILI. Among our two cases of avacopan-related VBDS, one patient recovered after discontinuation of avacopan, whereas the other progressed to severe liver injury leading to death.Conclusion 【Conclusion】Because avacopan-related VBDS can progrese to severe DILI, careful monitoring of liver function is essential after initiation of avacopan."

Clinical • ANCA Vasculitis • Glomerulonephritis • Hepatology • Liver Failure • Lupus Nephritis • Nephrology • Vasculitis

Ursodeoxycholic Acid Alleviates DSS/AOM-Induced Colorectal Cancer in Mice by Inhibiting PI3K/Akt/mTOR Signaling Pathway. (PubMed, Drug Des Devel Ther) - "These findings suggest that UDCA exerts its anti-tumor effects primarily through direct inhibition of the EGFR-mediated PI3K/Akt/mTOR pathway, accompanied by partial restoration of the intestinal immune-metabolic microenvironment. This study provides new mechanistic insights supporting the therapeutic application of UDCA in CRC."

Journal • Preclinical • Colorectal Cancer • Gastroenterology • Gastrointestinal Disorder • Immunology • Oncology • Solid Tumor • CYP19A1 • EGFR

Consensus statements of the Hellenic Autoimmune Liver Diseases Study Group on the diagnosis and current management of primary biliary cholangitis. (PubMed, Ann Gastroenterol) - "After 6-12 months of therapy with first-line treatment (13-15 mg/kg/day ursodeoxycholic acid [UDCA]), a new risk-stratification procedure should be performed, based on the assessment of biochemical response using a continuous scoring system (either GLOBE or UK-PBC score). In non-responders, add-on treatment to UDCA with a second-line agent, a proliferator-activated receptor agonist (PPAR), either elafibranor (PPARα/δ agonist) or seladelpar (PPARδ agonist), is recommended. The treatment target-also known as deep response-should aim to achieve bilirubin within the normal range, specifically at values <0.6× upper limit of normal, along with normalization of alkaline phosphatase. The disease-associated major symptoms (pruritus, fatigue and cognitive dysfunction) should also be promptly recognized and managed in a holistic manner, as they negatively affect the patient's health-related quality of life."

Journal • Cholestasis • Cognitive Disorders • Dermatology • Fatigue • Fibrosis • Hepatology • Immunology • Primary Biliary Cholangitis • Pruritus • PPARA

Meta-Analysis: PPAR Agonists for Pruritus and Quality of Life in Primary Biliary Cholangitis. (PubMed, Aliment Pharmacol Ther) - "PPAR agonists, notably bezafibrate and seladelpar, reduce pruritus severity in PBC patients with moderate-to-severe symptoms and consistently improve itch-specific outcomes. However, effects on global HRQoL remain uncertain. These findings underscore the incorporation of validated, symptom-focused endpoints in future PBC trials."

HEOR • Journal • Retrospective data • Review • Dermatology • Hepatology • Immunology • Primary Biliary Cholangitis • Pruritus

Metformin and ursodeoxycholic acid for the treatment of post-acute sequelae of COVID-19: a randomised clinical trial (ESCMID Global 2026) - No abstract available

Clinical • Infectious Disease • Novel Coronavirus Disease

Terbinafine-induced liver injury with isolated serum alkaline phosphatase elevation: A case report and literature review. (PubMed, J Int Med Res) - "In cholestatic drug-induced liver injury, serum liver function tests typically demonstrate concurrent elevations in alkaline phosphatase and γ-glutamyltransferase, with or without increases in alanine aminotransferase, aspartate aminotransferase, and total bilirubin. Following treatment with ursodeoxycholic acid, the patient achieved complete recovery. Clinicians should recognize that drug-induced liver injury may also present as an isolated elevation of alkaline phosphatase."

Journal • Review • Hepatology • Liver Failure

Baseline Determinants of Inadequate Ursodeoxycholic Acid Response in Primary Biliary Cholangitis: A POISE-Based Real-World Cohort Study (APASL 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Hepatology • Immunology • Primary Biliary Cholangitis

Predictors of response to ursodeoxycholic acid treatment and non-invasive identification of autoimmune hepatitis tendencies in primary biliary cholangitis (APASL 2026) - No abstract available

Non-invasive • Autoimmune Hepatitis • Hepatology • Immunology • Inflammation • Primary Biliary Cholangitis

Screening of new active molecules derived from ursodiol in the treatment of primary biliary cholangitis and ursodeoxycholic acid (APASL 2026) - No abstract available

Hepatology • Immunology • Primary Biliary Cholangitis

Efficacy of Sulfasalazine in Patients with Primary Biliary Cholangitis and Incomplete Response to Ursodeoxycholic Acid (APASL 2026) - No abstract available

Clinical • Hepatology • Immunology • Primary Biliary Cholangitis

Comparative efficacy of ursodeoxycholic acid and s-adenosyl methionine in reducing transaminases in patients with non-alcoholic steatohepatitis: a retrospective prospective cohort study (APASL 2026) - No abstract available

Retrospective data • Hepatology • Metabolic Dysfunction-Associated Steatohepatitis

Fenofibrate and ursodeoxycholic acid in treatment-naïve primary biliary cholangitis: a pilot randomized trial with integrated multi-omics analysis (APASL 2026) - No abstract available

Clinical • Hepatology • Immunology • Primary Biliary Cholangitis

AMA-negative Primary Biliary Cholangitis Diagnosed by a Reproducible Dechallenge-Rechallenge Response to Ursodeoxycholic Acid (APASL 2026) - No abstract available

Hepatology • Immunology • Primary Biliary Cholangitis

Prognosis of ursodeoxycholic acid-treated patients with primary biliary cholangitis: A single-center cohort study from China (APASL 2026) - No abstract available

Clinical • Hepatology • Immunology • Primary Biliary Cholangitis

Predictors of Incomplete Biochemical Response to Ursodeoxycholic Acid in Primary Biliary Cholangitis: Insights from a Moroccan Cohort (APASL 2026) - No abstract available

Hepatology • Immunology • Primary Biliary Cholangitis

Systemic Immune-Inflammation Index as a Predictive Biomarker for Non-Response to Ursodeoxycholic Acid in Primary Biliary Cholangitis (APASL 2026) - No abstract available

Biomarker • Hepatology • Immunology • Inflammation • Primary Biliary Cholangitis

Artificial intelligence-based prediction of ursodeoxycholic acid response in primary biliary cholangitis: comparison of two large language models (APASL 2026) - No abstract available

Hepatology • Immunology • Primary Biliary Cholangitis

Pruritus and Its Impact on Quality of Life in Primary Biliary Cholangitis: A Study of Patients on Long-Term Ursodeoxycholic Acid Treatment (APASL 2026) - No abstract available

Clinical • HEOR • Dermatology • Hepatology • Immunology • Primary Biliary Cholangitis • Pruritus

Efficacy & Safety of Oral Adjuvants to Phototherapy in Neonatal Hyperbilirubinemia (clinicaltrials.gov) - P4 | N=80 | Recruiting | Sponsor: Amira Adel Fouly | Not yet recruiting ➔ Recruiting | Trial completion date: Dec 2024 ➔ Jun 2026 | Trial primary completion date: Oct 2024 ➔ Jun 2026

Enrollment open • Trial completion date • Trial primary completion date